Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Eovist®' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Eovist®' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
MRI Resources 
Artifacts - Diffusion Weighted Imaging - - Equipment - Services and Supplies - Blood Flow Imaging
 
Eovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer
 
• Share the entry 'Eovist®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
HIGHLIGHTS OF PRESCRIBING INFORMATION
2008   by berlex.bayerhealthcare.com    
MRI Resources 
Anatomy - Lung Imaging - Research Labs - Hospitals - Colonography - Corporations
 
Primovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
for sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Primovist™
for sale
spacer

• View the DATABASE results for 'Primovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
New MRI liver contrast agent Primovist® approved in EU
Thursday, 30 September 2004   by www.secinfo.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
  News & More:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
MRI Resources 
Corporations - Shielding - Nerve Stimulator - Spectroscopy - Jobs - Colonography
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:
Contact Information
MAIL
Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE
+49-30-46-81-2431
FAX
+49-30-46-81-8195
spacer

• View the DATABASE results for 'Bayer Schering Pharma AG' (22).Open this link in a new window


• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
MRI Resources 
Blood Flow Imaging - Veterinary MRI - Contrast Agents - Colonography - Stent - General
 
Gadoxetic AcidInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-EOB-DTPA, generic name: Gadoxetic acid, chemical compound: Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Primovist™ (formerly Eovist®) is a nonionic water-soluble liver tissue-specific MRI contrast agent with positive enhancement. The agent allows detection and differentiation of hepatic tumors due to specific uptake by healthy liver tissue, but not by tumors in the affected organ. Gd-EOB-DTPA has hepatocyte-specific properties, but provides earlier perfusion information acquired within first ten minutes. Hepatocyte uptake generally occurs beyond 10 minutes.
spacer

• View the DATABASE results for 'Gadoxetic Acid' (6).Open this link in a new window

 
Further Reading:
  Basics:
Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study
Tuesday, 7 February 2017   by www.clinicaltrials.gov    
  News & More:
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
Thursday, 11 March 2021   by www.docwirenews.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
MRI Resources 
Safety Training - Abdominal Imaging - Absorption and Emission - Corporations - Research Labs - Chemistry
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]